| Document |
Document Title |
|
WO/2022/215566A1 |
[Problem] The present invention addresses the problem of discovering a molecule that is selectively expressed in mast cells and providing a prophylactic or therapeutic agent for allergic diseases. [Solution] This prophylactic or therapeu...
|
|
WO/2022/216965A1 |
Provided are methods for treating a solid cancer in a subject by administering an effective amount of a radioconjugated CCR8-targeting agent to deplete tumor-associated CCR8-positive Treg cells, alone or in combination with one or more a...
|
|
WO/2022/215679A1 |
The purpose of the present invention is to provide an antibody against pancreatic cancer stem cells. This antibody against pancreatic cancer stem cells includes a heavy chain variable region including heavy chain CDRs described as HCDR1-...
|
|
WO/2022/213895A1 |
The present invention provides a novel cationic lipid having a structure as shown in general formula (1) and particularly relates to a nitrogen-branched cationic lipid, and also relates to a liposome containing the cationic lipid, and a ...
|
|
WO/2022/215658A1 |
The present invention addresses the problem of providing a compound that binds to PGRMC1 and inhibits the function of PGRMC1. The present invention provides a PGRMC1 function inhibitor comprising glycyrrhizin, a glycyrrhizin derivative, ...
|
|
WO/2022/213664A1 |
The present invention belongs to the field of biomedicine, and mainly relates to an application of HDAC2 and DNMT1 inhibitors in the treatment of non-alcoholic steatohepatitis. The provided application of HDAC2 and DNMT1 inhibitors in th...
|
|
WO/2022/217059A1 |
Compounds comprising an isobaric region, an enrichment handle, and a thiol- reactive group are generally described. Methods of using the same (e.g., performing multiplexed quantitative analysis of the reactivity of one or more cysteine r...
|
|
WO/2022/213704A1 |
Provided are a high-migration mesenchymal stem cell, and a preparation method therefor and an application thereof. The preparation method comprises: inoculating and suspending mesenchymal stem cells in a mesenchymal stem cell culture sol...
|
|
WO/2022/214026A1 |
Disclosed in the present invention are a pegylated lipid and a preparation method therefor, a liposome comprising the pegylated lipid, and a pharmaceutical composition comprising the liposome and a preparation and use thereof, relating t...
|
|
WO/2022/217066A1 |
New methods, compositions and kits that comprise perampanel are provided for treating a subject having a SYNGAP1 neurodevelopmental disorder, including to treat conditions of sleep disorder, behavior problems and/or myoclonic or reflex s...
|
|
WO/2022/214455A1 |
The invention relates to compositions for the improvement of sport performance comprising Leucine, Isoleucine, Valine, Arginine and Glutamine, compounds of formula (I) and at least one acceptable carrier.
|
|
WO/2022/217116A1 |
This disclosure provides antibodies and antigen-binding fragments that can be administered to a subject that has been bitten by a venomous snake. Antibodies and antigen-binding fragments herein can be capable of treating or curing the su...
|
|
WO/2022/213502A1 |
Provided are an application of thyroxine in preparation of a drug for treating delayed embryonic development or incomplete embryonic development, an application of the thyroxine in preparation of a reagent for promoting growth, metabolis...
|
|
WO/2022/216101A1 |
The present invention relates to a novel indolizine derivative compound, and a composition for preventing or treating fibrosis or inflammatory diseases, comprising same as an active ingredient. An indolizine derivative of the present inv...
|
|
WO/2022/210829A1 |
Provided is a tablet: containing 55-95 mass% abiraterone acetate, as an active ingredient, to the total mass of the tablet, a solubilizing agent, and an aluminate metasilicate; being a small tablet having the content of abiraterone aceta...
|
|
WO/2022/208170A1 |
Use of a splicing modulator for a treatment slowing progression of Huntington's disease.
|
|
WO/2022/208976A1 |
The present invention addresses the problem of investigating whether serpinB2 can exhibit cell-activating activity as a result of skin external administration thereof, and providing a cell activator whereby stable quality can be ensured ...
|
|
WO/2022/211129A1 |
As an antisense oligonucleotide derivative that can suppress ATN1 gene expression and treat dentatorubral-pallidoluysian atrophy, the present invention provides a single-stranded oligonucleotide or a pharmaceutically acceptable salt ther...
|
|
WO/2022/210296A1 |
Provided are a new oxytocin signal enhancer and a new oxytocin-induced keratinocyte proliferation-promoting agent. The present invention provides an oxytocin signal enhancer and an oxytocin-induced keratinocyte proliferation-promoting ...
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/210232A1 |
The composition contains barley grass and is used to promote IgA secretion into saliva, to maintain or improve oral cavity immune function or mucous membrane immune function, and to prevent or mitigate upper respiratory tract infections.
|
|
WO/2022/210524A1 |
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation. This problem is solved by a nitrogen-containing compound represented by general formula (I...
|
|
WO/2022/209593A1 |
The present invention provides a cytokine production suppressing composition containing D-allose as an active component. The present invention further provides a method of treating or preventing diseases associated with cytokine overprod...
|
|
WO/2022/210802A1 |
The purpose of the present invention is to provide a novel agent for the prevention or treatment of muscular atrophy. The present invention provides an agent for the prevention or treatment of muscular atrophy, wherein the agent contains...
|
|
WO/2022/207846A1 |
This invention relates to antibodies that bind to and inhibit the activity of glial cell-derived neurotrophic factor family receptor alpha like (GFRAL) protein. The invention also relates to the GDF15-GFRAL signalling pathway as a therap...
|
|
WO/2022/211481A1 |
The present invention relates to: oral nanoparticles for enabling oral administration of a bioactive compound which is typically administered by injection due to having low bioavailability attributable to issues with solubility, disinteg...
|
|
WO/2022/212529A1 |
A transdermal system for providing estrogen to a patient in need thereof is provided. The transdermal system comprises a backing, and a matrix contacting the backing, the matrix configured to release about 4 mcg per day to about 36 mcg p...
|
|
WO/2022/211027A1 |
The present invention provides: a CD9 signal suppressing agent that includes the amino acid sequence of RSHRLRLH (SEQ ID NO: 1) or includes the SEQ ID NO: 1 amino acid sequence where one or more amino acids are deleted, substituted, or a...
|
|
WO/2022/210514A1 |
Previously there has not been a method for producing a highly safe cell preparation which, as far as is possible, does not include components of xenogenic origin, in order to reduce cross-species rejection and the risk of transmission of...
|
|
WO/2022/210224A1 |
Provided are: a cell preparation production method with which it is possible to produce, in a simple manner, an effective cell preparation by applying an appropriate hypoxic low-sugar stimulation to peripheral blood mononuclear cells; an...
|
|
WO/2022/210536A1 |
Provided is a method for producing a composition, which contains a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof and has a moisture content of at most 4.0 mass%, the method comprising irradiatin...
|
|
WO/2022/206705A1 |
The present invention provides a heterocyclic compound as a TYK2 pseudokinase (JH2) domain inhibitor, a synthetic method, and use. In particular, the present invention provides a heterocyclic compound as represented by formula I, or a ph...
|
|
WO/2022/211060A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound repre...
|
|
WO/2022/202477A1 |
[Problem] To provide a safe prophylactic agent or therapeutic agent for side effects of an anthracycline anticancer agent, the agent having a broad range of applications. [Solution] In a treatment of a cancer using an anthracycline antic...
|
|
WO/2022/204429A1 |
Microglia are an essential part of the immune system in the central nervous system, as well as potential sources of disease. Gene silencing employs short interfering RNA (siRNA) to selectively target genes that are the source of such dis...
|
|
WO/2022/200857A1 |
The present disclosure relates to a. compound of formula I or a. pharmaceutically acceptable salt thereof Formula I wherein A is Formula II X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 m...
|
|
WO/2022/202761A1 |
[Problem] To provide a peptide complex capable of binding to c-Met protein. [Solution] Provided is a peptide complex containing a peptide A, in which the peptide A is a peptide comprising the amino acid sequence represented by X1-X2-X3-V...
|
|
WO/2022/202403A1 |
Provided is a material that is useful for increasing the Neisseria mucosa content in the oral cavity. This oral Neisseria-mucosa-increasing agent has, as active ingredients, a nitrate-ion-supplying compound and one or more sugar alcoho...
|
|
WO/2022/203384A1 |
The present invention may provide information relating to an appropriate injection amount, of magnetic cells injected into the body, which is required to achieve a desired strain rate in a target tissue. Further, a composition comprising...
|
|
WO/2022/203543A1 |
The invention relates to the field of gerontology, and more particularly to the possibility of acting on the expression profile of certain genes in human blood plasma which are associated with biological aging by administering an amarant...
|
|
WO/2022/198438A1 |
Disclosed are ligand-bound zinc sulfide nanoparticles, the method of preparing the ligand-bound zinc sulfide nanoparticles, composition containing ligand-bound zinc sulfide nanoparticles, uses of ligand-bound zinc sulfide nanoparticles a...
|
|
WO/2022/203547A1 |
The invention relates to medicine, and more particularly to midwifery, and is intended for treating gestosis in the first trimester of pregnancy. For treating gestosis in the first trimester of pregnancy, the use of a phospholipid emulsi...
|
|
WO/2022/203571A1 |
The invention relates to a combination comprising an effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, and an effective amount of heparin, or a pharmaceutically acceptable salt thereof, for use in treatm...
|
|
WO/2022/201775A1 |
An intestinal bacteria count reducing agent according to one aspect of the present invention contains silicon particles or silicon fine particles and reduces the number of intestinal bacteria. By using this intestinal bacteria count redu...
|
|
WO/2022/200608A1 |
The present invention relates to composition comprising at least a compound having general formula (I) for use in (i) increasing resistance to age-related pathologies, (ii) improving a physiological state or disorder related to cell agei...
|
|
WO/2022/204369A1 |
This disclosure relates to messenger RNA (mRNA) therapy for the treatment of methylmalonic acidemia. mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase. mRNA therapies of the disclosure increase an...
|
|
WO/2022/204517A1 |
This disclosure relates to formulations containing arginine and other ingredients useful in managing acute and chronic complications of coronavirus infections, including respiratory symptoms fatigue, hypercoagulable state, cardiac sympto...
|
|
WO/2022/202864A1 |
The present invention relates to: a compound, or a pharmacologically acceptable salt thereof, that has GLP-1 receptor agonist activity and that is useful as an agent for treating or preventing diseases involving the GLP-1 receptors; and ...
|
|
WO/2022/201832A1 |
The present invention addresses the problem of providing a novel GLP-1 secretion promotion agent. The present invention provides a GLP-1 secretion promotion agent that includes a GPR84 agonist as an active ingredient.
|
|
WO/2022/202947A1 |
Disclosed is a stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition that comprises a protein as an active ingredient. This pharmaceutical composition comprises a protein having a physiological activity and...
|
